Following these data and evidence from other key clinical trials, the U.S. Preventative Services Task Force (USPSTF) recently released guidelines advising against PSA-based screening for prostate cancer in asymptomatic men [12]. This evidence concerns the gene KLK3 and prostate carcinoma.